Easy automation and a shorter analysis time are advantages of the kinetic assay over the chromogenic procedure. By incorporation of standards containing the pancreatic or salivary isoamylase, results can be calculated with a simple calculator, avoiding the need to use a nonlinear calibration curve (13, 14 121, 11-14 (1982). 
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Clin Chem 28, 1787 Chem 28, -1791 Chem 28, (1982 (1) . A powerful inhibitor of the desmolase enzyme system, the drug blocks the conversion of cholesterol to A5-pregnenolone; it also inhibits the aromatase system, preventing the conversion of androgens to estrogens in nonadrenal tissues (2 Clinically, aminoglutethimide has been used to induce medical adrenalectomy and treat steroid-dependent breast cancer. However, side effects of drowsiness, ataxia, and rash necessitate in some cases cessation of treatment (1, 2) .
Prior methods for the measurement of plasma aminoglutethimide have been based on organic extraction, followed by color development with a relatively nonspecific reagent (3) . We have developed a simple method involving protein precipitation by acetonitrile, liquid-chromatographic separation, and detection of ultraviolet absorbance.
The method
is accurate, precise, rapid, and simple to perform.
Materials and Methods

Apparatus.
The chromatographic system consisted of a M600A pump, a U6K universal The mobile phase consisted of 3 mL of Pic A added to a mixture of 100 mL of acetonitrile and 100 mL of distilled water. The solution was adjusted to pH 6.3 ± 0.2 with orthophosphoric acid. Immediately before use the mobile phase was ifitered through a 0.5-sm pore-size filter (Millipore Corp.; FHUP 04700) and degassed. A stock aminoglutethimide standard was prepared by dissolving 23.2 mg of aminoglutethimide ("Elipten"; obtained from Ciba-Geigy Australia Ltd., and used without further purification) in 100 mL of distilled water (1 mmolIL). The working standard was prepared by diluting 10 mL of stock solution to 100 mL of mobile phase (0.1 mmolIL). Both standard solutions were stable for at least three months when stored at 4 #{176}C.
Procedure.
To a 0.1-mL aliquot of plasma in a 1.5-mL centrifuge tube (EV292; Filtrona Plastics, Thomastown, Victoria, Australia 3074) add 0.2 mL of acetronitrile.
Vortex-mix for 15 s and then centrifuge at 12500 x g for 1 mm The flow rate of the mobile phase is 2.0 mL/min and the column is kept at ambient temperature (22 #{176}C). The detection wavelengths are set at 240/254 nm with a span of 0.02 absorbance units fdll-scale deflection.
Measure peak heights of samples, controls, and standard at 240 and 254 nm and calculate the plasma aminoglutethinude concentrations at each wavelength according to the following equations.
If the results calculated at the two wavelengths differ by more than 5%, then a co-eluting compound is assumed to be present. Accurate quantification in this case necessitates a change in chromatographic conditions to separate the interfering compound from the aminoglutethimide. Figure 1 shows a chromatogram of an aminoglutethimide standard and two patients'samples. The aminoglutethimide has a retention time of 2.5 mm, corresponding to a retention volume of 5 mL. Although aminoglutethimide is not resolved completely from the preceding peak, other experiments (not shown) on patients' sera before medication, or after cessation of treatment, indicate that the preceding peak has returned to baseline before 2.5 nun.
Results
Results using this method are linear to a plasma concentration of at least 1.5 mmol/L (10 ninol injected onto the column), 30-foldthe upper limitof the therapeutic range. As estimated from the peak-to-noise ratio, the limit of detectability of aininoglutethimide is less than 1 mol/L in plasma.
We performed recovery and imprecision studies on pooled plasma supplemented with aminoglutethimide at two concentrations. Recovery at 20 LmolfL ranged from 100 to 110%, mean 107% (n = 20); within-batch imprecision (CV) was 2.3% (n = 20) and between-batch was 3.6% (n = 10). Recovery at 100 .Lmol/L ranged from 98 to 105% mean 102% (n = 20); within-batch imprecision (CV) was 2.0% (n = 20) and between-batch was 2.2% (n = 10).
Also with pooled plasma, we assessed the stability of drug-containing specimens stored at 4 and -20 #{176}C. At 4#{176}C the plasma aminoglutethimide concentration decreased by 10-20% over a seven-day period whereas at -20 #{176}C it was stable for at least three months.
At the time of publication we have analyzed more than detected by a change in the peak height ratio at the two detectionwavelengths.
Discussion
With this procedure aminoglutethimide can be accurately and precisely determined in plasma. Reagent costs are low and the method is both rapid and robust, making it an attractive alternative to current colorimetric techniques.
Extra peaks other than aminoglutethimide are observed on chromatograms of patients receiving medication. These are presumably metabolites of aminoglutethimide and further work is in progress to confirm this assumption. Despite the fact that little is known about the pharmacological effects of aminoglutethimide metabolites, the measurement of plasma aminoglutethimide has proved useful clinically and has been in routine use in our institute for approximately 12 months. Our results indicate toxic concentrations are reached at approximately 70 .tmoliL in plasma, the provisional therapeutic range being 20-50 zmol/L.
